Replies to post #146913 on Biotech Values

[mcbio]

Regardless, small cap oncology companies have performed horribly the past month.

It is frustrating watching CLDX trade for ~$275-300 million marketcap - because, I really believe this company has one of the most impressive potential pipelines out there right now. Think about the programs this company has, of which 2 are late stage and represent big opportunities - and then think about some complete junk in biotech which is trading at comparable, if not much higher, market caps. Frustrating.

I'll play nice and just say I find it quite surprising that CLDX trades in the same ballpark of valuation as PPHM. That makes no sense to me. Hopefully that will be corrected in due time.